Brooks Laboratories Limited (BROOKS.NS)
INR 156.86
(2.0%)
INR 156.86
(2.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 904.45 Million INR | -17.47% |
| 2022 | 1.09 Billion INR | -44.06% |
| 2021 | 1.95 Billion INR | 20.87% |
| 2020 | 1.62 Billion INR | 2.67% |
| 2019 | 1.57 Billion INR | -6.01% |
| 2018 | 1.67 Billion INR | -2.73% |
| 2017 | 1.72 Billion INR | 5.87% |
| 2016 | 1.63 Billion INR | 6.92% |
| 2015 | 1.52 Billion INR | 12.87% |
| 2014 | 1.35 Billion INR | -3.77% |
| 2013 | 1.4 Billion INR | 6.67% |
| 2012 | 1.31 Billion INR | 24.44% |
| 2011 | 1.05 Billion INR | 158.92% |
| 2010 | 408.63 Million INR | 9.68% |
| 2009 | 372.56 Million INR | 16.0% |
| 2008 | 321.18 Million INR | 26.54% |
| 2007 | 253.81 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 1.05 Billion INR | 0.0% |
| 2023 FY | 904.45 Million INR | -17.47% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 904.45 Million INR | 0.0% |
| 2022 Q2 | 2.09 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 1.09 Billion INR | -44.06% |
| 2022 Q4 | 1.09 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 1.95 Billion INR | 20.87% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 1.95 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 1.74 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 1.62 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 1.75 Billion INR | 0.0% |
| 2020 FY | 1.62 Billion INR | 2.67% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 1.57 Billion INR | -6.01% |
| 2019 Q2 | 1.71 Billion INR | 0.0% |
| 2019 Q4 | 1.57 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 1.67 Billion INR | 0.0% |
| 2018 FY | 1.67 Billion INR | -2.73% |
| 2018 Q2 | 1.69 Billion INR | 0.0% |
| 2017 Q2 | 1.72 Billion INR | 0.0% |
| 2017 FY | 1.72 Billion INR | 5.87% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 1.72 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q2 | 1.59 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 1.63 Billion INR | 0.0% |
| 2016 FY | 1.63 Billion INR | 6.92% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 1.52 Billion INR | 12.87% |
| 2015 Q4 | 1.52 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 1.57 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 1.32 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 1.35 Billion INR | -3.77% |
| 2014 Q4 | 1.35 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 1.4 Billion INR | 6.67% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 1.4 Billion INR | 0.0% |
| 2013 Q2 | 1.42 Billion INR | 0.0% |
| 2012 FY | 1.31 Billion INR | 24.44% |
| 2012 Q2 | 1.17 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q4 | 1.31 Billion INR | 0.0% |
| 2011 FY | 1.05 Billion INR | 158.92% |
| 2011 Q4 | 1.05 Billion INR | 0.0% |
| 2010 FY | 408.63 Million INR | 9.68% |
| 2009 FY | 372.56 Million INR | 16.0% |
| 2008 FY | 321.18 Million INR | 26.54% |
| 2007 FY | 253.81 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Sigachi Industries Limited | 6.94 Billion INR | 86.97% |
| Ind-Swift Limited | 6.54 Billion INR | 86.18% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 88.179% |
| Sakar Healthcare Limited | 3.88 Billion INR | 76.729% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 99.799% |
| Innova Captab Limited | 13.2 Billion INR | 93.153% |
| Divi's Laboratories Limited | 154.7 Billion INR | 99.415% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 91.61% |
| Morepen Laboratories Limited | 12.93 Billion INR | 93.006% |
| Mankind Pharma Limited | 119.63 Billion INR | 99.244% |
| Sequent Scientific Limited | 15.4 Billion INR | 94.128% |
| Wanbury Limited | 3.43 Billion INR | 73.669% |
| Laurus Labs Limited | 83.87 Billion INR | 98.922% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 95.872% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 96.827% |
| Alembic Limited | 23.28 Billion INR | 96.116% |
| Hikal Limited | 24.87 Billion INR | 96.363% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 98.597% |
| Neuland Laboratories Limited | 18.32 Billion INR | 95.065% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 97.736% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 99.37% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 95.97% |
| Themis Medicare Limited | 5.66 Billion INR | 84.032% |
| RPG Life Sciences Limited | 5.12 Billion INR | 82.365% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 99.691% |
| Lupin Limited | 239.97 Billion INR | 99.623% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | 75.347% |
| Wockhardt Limited | 76.49 Billion INR | 98.818% |
| Vaishali Pharma Limited | 799.55 Million INR | -13.119% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 96.497% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | 58.335% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 99.217% |
| FDC Limited | 24.68 Billion INR | 96.335% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 99.767% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | 62.324% |
| Eris Lifesciences Limited | 70.48 Billion INR | 98.717% |
| Venus Remedies Limited | 6.26 Billion INR | 85.571% |
| ZIM Laboratories Limited | 4.46 Billion INR | 79.758% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 92.549% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | 10.989% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 96.647% |
| Shilpa Medicare Limited | 30.93 Billion INR | 97.076% |
| Albert David Limited | 4.97 Billion INR | 81.838% |
| Ajanta Pharma Limited | 46.38 Billion INR | 98.05% |
| Hester Biosciences Limited | 6.62 Billion INR | 86.345% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 95.987% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 96.146% |
| Gufic Biosciences Limited | 10.92 Billion INR | 91.722% |
| Windlas Biotech Limited | 6.26 Billion INR | 85.557% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 88.614% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | 70.345% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | 72.874% |
| Granules India Limited | 55.2 Billion INR | 98.362% |
| Aarti Drugs Limited | 24.32 Billion INR | 96.282% |
| Bal Pharma Limited | 3.2 Billion INR | 71.77% |
| Alkem Laboratories Limited | 155.74 Billion INR | 99.419% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.894% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | 87.085% |
| Medicamen Biotech Limited | 2.94 Billion INR | 69.291% |
| Unichem Laboratories Limited | 31.69 Billion INR | 97.146% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | 38.756% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -92.099% |
| Valiant Laboratories Limited | 3.42 Billion INR | 73.607% |
| Orchid Pharma Limited | 15.53 Billion INR | 94.179% |
| Medico Remedies Limited | 961.95 Million INR | 5.977% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 92.237% |
| Ipca Laboratories Limited | 111.01 Billion INR | 99.185% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | 77.649% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.891% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 99.399% |
| NATCO Pharma Limited | 69.06 Billion INR | 98.69% |
| Suven Life Sciences Limited | 2.84 Billion INR | 68.254% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | 49.238% |
| Strides Pharma Science Limited | 58.39 Billion INR | 98.451% |
| Indoco Remedies Limited | 21.44 Billion INR | 95.783% |
| Alpa Laboratories Limited | 1.82 Billion INR | 50.474% |
| Lasa Supergenerics Limited | 1.5 Billion INR | 40.05% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | 82.439% |